You are here: Industry Insights > bluebird bio

News List

bluebird bio Presents New Data for LentiGlobin Gene Therapy in Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology firstwordpharma
December 05, 2018
SCD is a serious, progressively debilitating and life-threatening genetic disease. SCD results from production of abnormal sickle hemoglobin (HbS), which leads to sickled red blood cells (RBCs) and hemolysis.
bluebird bio, Gritstone Enter Collaboration contractpharma
August 28, 2018
bluebird bio, Inc. and Gritstone Oncology, Inc. announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy.
Bluebird Bio and Gritstone Oncology partner on cancer cell therapies pharmaceutical
August 27, 2018
US-based biotechnology companies Bluebird Bio and Gritstone Oncology have entered into strategic collaboration for the development of new cancer cell therapies.
Regeneron and Bluebird Bio collaborate on T-cells in $100 million deal pharmatimes
August 07, 2018
Regeneron and Bluebird Bio have announced that they will collaboration to apply their respective technology platforms to the discovery, development and commercialisation of novel immune cell therapies for cancer.
Medigene and bluebird bio expand immunotherapy partnership to $1.5bn pharmafile
May 15, 2018
Medigene has announced that it has bolstered the existing partnership it has in place with US firm bluebird bio, originally signed in 2016, bringing the total potential value of the deal to $1.5 billion.
Bluebird Bio One Step Closer to its First Approved Drug biospace
April 23, 2018
Bluebird bio, headquartered in Cambridge, Massachusetts, announced interim data from two different two-year clinical trials of LentiGlobin gene therapy for transfusion-dependent beta-thalassemia (TDT).
Celgene and bluebird bio Team Up in New Deal biospace
March 29, 2018
Celgene Corporation and bluebird bio have inked a development and promotion deal for bb2121, bluebird’s B-cell maturation antigen (BCMA) CAR-T therapy for relapsed/refractory multiple myeloma (rrMM).
Merck to work with bluebird bio on viral vector manufacturing pharmaasia
January 04, 2018
Merck aims to accelerate its manufacturing of new treatments for a broad range of serious diseases via this collaboration.
Bluebird Bio Expects Europe as first market for its gene therapies fiercebiotech
August 08, 2017
Bluebird Bio seeks to bring its gene therapies to European Market before the U.S., taking the advantages of a favorable regulatory pathway, which is appealing to the pharmaceutical companies.

Previous page 1 2 Next page